The FY23 Defense Appropriations Act is anticipated to provide funding for the TSCRP to support innovative, high-impact tuberous sclerosis complex (TSC) research. The managing agent for the anticipated funding opportunities is the CDMRP at the U.S. Army Medical Research and Development Command (USAMRDC).
The FY23 TSCRP funding opportunity announcements for the following award mechanisms are posted on the Grants.gov website.
Applications submitted to the FY23 TSCRP must address one or more of the following Focus Areas:
- Understanding, preventing, and treating the features of TSC-Associated Neuropsychiatric Disorders (TAND) and reducing their impact, including pharmacological, behavioral, and surgical interventions
- Strategies for eradicating tumors associated with TSC and TSC-associated lymphangioleiomyomatosis (LAM), including gaining a deeper mechanistic understanding of tumor microenvironment, TSC signaling and mTOR-independent pathways
- Preventing, epilepsy, improving treatment, and mitigating neurodevelopmental and adverse outcomes associated with TSC-related seizures
- Developing, assessing, and testing emerging technologies including imaging and molecular therapeutic strategies, such as gene therapy, to improve outcomes in TSC
There are three Funding Mechanisms availavble:
- Exploration – Hypothesis Development Award (EHDA)
- Idea Development Award (IDA)
- Clinical Translational Research Award (CTRA)
A pre-application is required and must be submitted through the electronic Biomedical Research Application Portal (eBRAP) at https://eBRAP.org prior to the pre-application deadline: June 8, 2023
5 pm Eastern Time (ET).